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Evaluation of the regional nurse-supported
hepatitis C shared care program in Western
Australia: a mixed methods study
Roanna Lobo1*†, Lester Mascarenhas2†, David Worthington3, Judith Bevan3 and Donna B. Mak3,4

Abstract
Background: Nurse-supported shared care services for patients living with hepatitis C have been implemented in
some regional areas of Western Australia to provide access to local treatment and care services for patients and to
improve currently low levels of treatment uptake. This study collected data from health professionals involved in
managing the care of patients living with hepatitis C and from patients engaged in regional nurse-supported
hepatitis C shared care services in Western Australia.
Methods: Key informant qualitative interviews were conducted with health professionals in regions operating a
nurse-supported shared care service and in regions without this service. Patients engaged in the shared care
program at the time of the study were invited to complete a short questionnaire.
Results: Nurse-supported shared care services reduced patient transport costs to tertiary centres, accelerated access
to treatment and delivered >98 % compliance with treatment schedules. Patients engaged with regional hepatitis C
shared care services expressed high levels of satisfaction and indicated that they would delay treatment if it was
not available locally. Telehealth support from tertiary liver clinics and allied health services were available to health
professionals engaged in regional shared care services and were used effectively. There was limited participation by
general practitioners in regional hepatitis C shared care services and regional patients’ access to treatment was
influenced by the availability and capacity of health professionals. Uptake of treatment and engagement in the
regional shared care program was limited for Aboriginal people and younger people although these groups had
the highest rates of hepatitis C notifications in Western Australia.
Discussion: The patients consulted for this study preferred to access hepatitis C treatment and care locally rather
than travel to tertiary liver clinics, up to 1500 kilometres away. The reasons for limited engagement in the shared
care program by some groups with high rates of hepatitis C notifications requires further investigation. Health
professionals identified several benefits of the shared care program including continuity of care for patients, shorter
waiting times, longer appointment times and high levels of treatment compliance.
Conclusions: Hepatitis nurses in regional areas can coordinate effective patient treatment and care when
supported by treatment protocols and access to physicians and liver specialists, including through telehealth.
Treatment and care options to suit individual preferences are required to avoid further stigmatising marginalised
groups. The role of primary care in facilitating hepatitis C treatment uptake should be explored further including
strategies for improving the participation of general practitioners in regional shared care services.
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Background
Hepatitis C is a viral infection of the liver and a major
public health issue in Western Australia (WA) affecting
around 0.8 % of the population with over 1,000 cases
notified to the WA Department of Health each year [1].
The majority of notifications are in people aged 20 to
34 years and the most commonly reported risk factor for
infection is injecting drug use [2]. In 2012, the WA newly
acquired hepatitis C infection rate, where there is evidence
of infection occurring in the last 24 months, was more
than double the national rate, 5.3 compared with 2.6/
100,000 population. For unspecified hepatitis C, where infections have unknown duration, notification rates in WA
(43/100,000 population) remained comparable to national
rates. Aboriginal1 to non-Aboriginal rate ratios for newly
acquired and unspecified infections were higher, 13:1 and
7:1 respectively [2]. Of those infected, 75-80 % will develop
chronic hepatitis C virus (HCV) infection and without
treatment, 10-15 % of these patients will develop liver
cirrhosis leading to liver cancer in approximately 5 % of
patients [1].
Currently available treatments involving six- to ninemonth courses of pegylated interferon alpha in combination with ribavirin or another oral antiviral drug offer a
cure rate of around 60 % [3]. This rate is likely to increase
to above 90 % with new oral treatments becoming available
[4]. However, the number of people accessing hepatitis C
treatment in Australia is low. There are an estimated 2,808
people receiving treatment through the Highly Specialised
Drugs Program [5], equating to approximately 1.2 % of the
estimated 230,000 people living in Australia with chronic
hepatitis C infection [5]. Factors contributing to low uptake
of treatment are varied and include lengthy treatment regimens, severe side effects, stigma and social inclusion issues,
and limited availability of services [4, 6]. Diagnosis at a time
prior to treatment being available, reluctance to begin treatment and lack of awareness on the part of both patients
and general practitioners (GPs) about improvements in the
available treatments may also be contributing factors [7].
The newer hepatitis C treatments which have shorter
treatment schedules and fewer side effects may contribute
to increased treatment uptake in Australia if they can be
made available at an affordable cost. Stigma and social
inclusion issues affecting treatment uptake have been addressed through various strategies. For example, a trial in
New South Wales co-locating hepatitis C treatment services with other services for people who inject drugs
(PWID) has shown promise in reducing the negative and
stigmatising experiences reported by hepatitis C patients seeking treatment in other settings [8]. Hepatitis
C treatment delivered through primary care settings
has also been piloted successfully and may be an option
for selected patients with HCV infection to improve access to treatment [6].
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Shared care models also have a role in improving service
accessibility for patients living with HCV infection. In the
2nd edition of the Hepatitis C Resource Manual, shared care
is described as “a system that operates between GPs/physicians in rural or remote areas and liver specialists in major
regional centres. The aim of shared care is to provide
optimum input for people who live in rural or remote areas
by reducing their travel time and expenses, whilst still having access to medical interventions.” ([9], p.144). Multisectoral participation and partnerships between primary
care providers and tertiary specialists are features of all
shared care models.
Shared care models for hepatitis C have been trialled
in Australia in the primary care sector with promising
results [6, 7, 10, 11]. The benefits of shared care included improved service accessibility, increased patient
compliance, increased likelihood of patients completing
treatment, reduced travel costs for patients able to
access treatment locally, and reduced demand on tertiary
clinics for appointments [10, 11].
Given the high rates of HCV infection amongst PWID
and high rates of imprisonment of PWID, custodial settings
also present an opportunity to engage these marginalised
populations. Shared care models targeting people in custodial settings have been shown to be effective in reducing
the burden of HCV infection and increasing treatment
uptake [12, 13].
Nurse-led models of shared care have been implemented for patients with chronic diseases in regional,
rural and remote areas and have demonstrated additional
benefits. Examples include: cultural acceptability for Aboriginal patients with renal disease [14]; helping to address
the growing demand for chronic disease management by
general practitioners [15]; and improved diabetes selfmanagement by patients through opportunities to discuss
complex issues with nurses more fully [16].
WA regional nurse-supported hepatitis C shared care
services

Regional nurse-supported hepatitis C shared care services
were first implemented in the Great Southern and South
West regions of WA in 2003 and have been available in
the Kimberley region of WA since 2004. The services are
funded by the WA Department of Health Sexual Health
and Blood-borne Virus Program (SHBBVP) and employ
dedicated hepatitis nurses to improve access to and uptake
of hepatitis C treatment for patients with HCV living in
regional, rural and remote areas.
The regional nurse-supported shared care program is a
patient-centred model, primarily intended to deliver benefits to patients. Secondary benefits for health professionals
may include support to engage patients in treatment and
care and improved pathology workup and patient education
prior to seeing the physician. The hepatitis nurses facilitate
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liaison between a patient and their GP, physician, and/or
tertiary health services and assist patient access to allied
health services including mental health services and drug
and alcohol services. In 2011, WA had 183.5 GPs per
100,000 persons, the lowest per capita rate of GPs in
Australia. The number of GPs in regional areas of Australia
was also almost 57 % lower than in major cities [17].
This study evaluated the WA regional nurse-supported
hepatitis C shared care program and the implications for
WA regions without nurse-supported hepatitis C shared
care services. The study collected data on the benefits,
critical features, challenges and enablers of the shared care
model and identified opportunities for improving access
to hepatitis treatment and care for patients living in regional areas.

Methods
WA health professionals involved in managing the care of
patients with HCV infection (GPs, liver specialists, physicians, public health nurses and hepatitis nurses) and patients engaged with the WA regional nurse-supported
hepatitis C shared care program provided data for this
study.
Key informant interviews

Sixteen health professionals involved in management of
patients with hepatitis C were identified as key informants
by the WA Department of Health SHBBVP. They received
an email from the evaluation team informing them of the
evaluation project and its aims and requesting their participation. In-depth semi-structured qualitative interviews were
chosen for their potential to elicit rich information from
the perspectives of key informants [18]. The interview
questions were derived from interview guides used in a
previous evaluation of hepatitis C shared care services. The
questions explored which aspects of the program worked
well and areas noted for improvement [11]. All interviews
were conducted by a public health registrar (LM) who had
no prior relationship with the key informants and who
was independent of the WA nurse-supported regional
shared care services program. In regions without a nursesupported shared care service, semi-structured interviews
were conducted by LM with physicians and public health
nurses to understand any regional differences in services
and patient needs. The interviews also aimed to assess the
consequences and implications of the absence of a nursesupported shared care program, including influences on
service delivery, health service resources, and patients’ access to and uptake of treatment.
Interviews were conducted face-to-face whenever possible or by using web-cam based software or telephone.
Written consent from participants was obtained to
record the interviews to improve reliability of the data.
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Participation was voluntary and participants could withdraw from the study at any time.
The interview data were transcribed verbatim and
thematic content analysis was used to establish an understanding of their meaning. The analysis process
involved reading the transcripts and searching for
patterns (“themes”) in the data which were then used to
organise and describe the data, a process known as
coding [19]. All transcripts were coded by another researcher (RL) to ensure that all themes had been identified and that coding was consistent. Confirmability of
the interview transcripts and coding process was further
supported through handwritten notes recorded by the
interviewer (LM) [20].

Patient survey

A short survey was created based on a patient survey
used in a previous evaluation of hepatitis C shared care
services [11]. The paper-based survey comprised 19
questions and included Yes/No questions, multiple
choice questions and one open ended question. The survey was designed to be self-completed within 5–10 min
and survey responses were anonymous. Written consent
was required from participants. Fifty-one patients, comprising those currently receiving treatment or posttreatment follow-up, were engaged with the WA regional nurse-supported hepatitis C shared care program
at the time of data collection. Regional hepatitis nurses
posted the survey with an information sheet, consent
form and reply paid envelope to 47 patients. Four patients were not invited to complete a survey; the reasons
for this were not recorded.
The survey was anonymous and sought information on
patient demographics; patterns of accessing health services;
reasons for commencing treatment; the types of professionals primarily responsible for treatment management
and support; perceptions of the quality of care, including
access to medication, support and information; and overall
impressions of and attitudes towards the shared care initiative. All patients received a reminder from their hepatitis
nurse to complete the survey. The results of the patient
survey were used to assess overall levels of patient satisfaction with the WA regional nurse-supported hepatitis C
shared care program and to compare the data collected
about patients’ experiences of treatment and care with data
collected from health professionals involved in the shared
care program.
Ethics approval for this study was obtained from the
WA Country Health Service Human Research Ethics
Committee (Ref: 2013:09). A reciprocal ethics agreement
was also obtained from the Curtin University Human
Research Ethics Committee (Approval Number HR11/
2014).
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Results
The results of the key informant interviews and patient
survey are presented below.
Key informant interviews

Two key informants declined to participate, two did not
respond to the invitation and one key informant was interested in the study but unable to find time to participate.
Overall, 11 key informants were interviewed. These
included the three regional hepatitis nurses, one GP and
two physicians based in the regions, and a tertiary liver
clinic specialist. Four key informant interviews were also
held with physicians and public health nurses in regions
which did not operate a nurse-supported hepatitis C shared
care program. The interviews ranged in duration between
20 min and 90 min. The face-to-face and web-cam interviews were longer than the telephone interviews and
enabled greater rapport between the interviewer and the
key informants.
Current operation of the WA regional nurse-supported
hepatitis C shared care model

The steps in the care pathway for a patient enrolled in the
WA regional nurse-supported hepatitis C shared care program were mapped based on key informants’ answers. The
steps are summarised below.
1. Self-referral by patient (or patient is referred by a
GP) to the hepatitis nurse. The hepatitis nurse
briefs the patient about the risks, benefits and
precautions of treatment. The hepatitis nurse
has several consultations with the patient,
performing a thorough assessment and
completing pathology workup before treatment
can commence. For initial appointments, the
hepatitis nurse would generally see patients
face-to-face. Once treatment was commenced,
some follow up may have been conducted over
the telephone due to the distance that may
otherwise have been required to travel (even
within regions) to attend appointments.
2. The hepatitis nurse refers the patient to allied health
services for psychological review or drug and alcohol
assessment and support if needed. Access to allied
health services in regional areas is variable and,
depending on needs, may be provided through
specialised services or managed by the GP, physician,
or nurse. After tests are complete, the hepatitis
nurse contacts the referring GP and makes
recommendations to them about the patient’s
condition and treatment.
3. When the patient consents to treatment the
hepatitis nurse schedules an appointment for the
patient to see the physician.
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4. The physician liaises with the hepatitis nurse and
the patient visits the nurse to receive their scripts,
receive counselling and begin treatment.
5. The hepatitis nurse coordinates all patient treatment
and care in consultation with the physician. The
tertiary liver clinics provide advice and support to
the physician and the hepatitis nurse on request.
6. Complex cases are referred to the tertiary liver
clinics by the physician.
Access to treatment

The key informant interviews identified a range of factors
that influenced whether regional patients received treatment and care when they needed it. Patient-related factors
included: patient’s medical condition (e.g. existence of any
co-morbidities); patient’s hepatitis C genotype (since treatment regimens can vary according to genotype); personal
circumstances of patient (e.g. lifestyle, age and work commitments); patient’s choice given possible side effects; and
patient’s willingness and commitment to attend initial
appointments and complete the treatment schedule.
Other factors influencing whether patients received treatment were associated with the capacity of regions to treat
and care for patients and included: delays in getting results
from psychological and drug and alcohol investigations;
capacity to follow up patients by specialist physicians; and
the experience and capacity of the hepatitis nurse.
Roles of health professionals in shared care

The nurse was seen to provide a constant point of contact
in a context of changing general practitioner locums in
some regional areas.
‘Most of the patients value the support from the nurse,
she’s very conscientious and makes sure that they’ve
had all their tests done and they’re up to date and
they know what’s going on and she informs them what
their test results are’ (Physician)
‘Patients don't want to see somebody different every
time’ (Nurse)
Tertiary centres provided education for GPs, nurses and
physicians and advised on complex cases. Patients with
cirrhosis or those requiring a liver transplant were referred
to tertiary centres by physicians. Mental health and alcohol and drug services were generally available and patients
could be referred to these services easily.
Perceived benefits of shared care services

Hepatitis nurses and physicians in the three regions with
a nurse-supported shared care model reported a range of
benefits including shorter waiting times; longer appointments; ability to be more responsive to patient needs;
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reduced transport costs for patients from regional locations to tertiary centres; increased adherence to treatment; and continuity of care.
‘6 or 8 weeks to see a physician and then starting
treatment within a week or two if they want to’.
(Physician)
‘GP appointments are only 15 odd minutes. Most of the
time when we [shared care service] see clients it’s
30 min. So we have time, we try to engage them quite
holistically reviewing where they’re at with not just their
physical health but other issues in their life’. (Nurse)
In particular, patient compliance with the treatment
schedule and the likelihood of patients completing treatment were very high, as indicated through compliance rates
of 98 – 100 %.
‘Very high probability patients will complete
treatment. I can only think of one who stopped
treatment’. (Nurse)
Challenges and enablers associated with implementation

Challenges identified by key informants related to implementing a regional nurse-supported shared care model
included: managing patients with high needs; high GP and
medical registrar turnover in regional areas; and limited
capacity of nurses and physicians to meet demands.
‘We’ve got 6 patients waiting who we would be treating
now if we had the nurse more days per week’.
(Physician)
Having an experienced nurse to decide when to consult
a physician, dedicated time for nurses to discuss patients
with a physician, and effective communication were noted
as enablers for successful implementation of the shared
care model.
‘It has to be a fairly experienced nurse. You don’t just
delegate it to someone without that clinical skill’.
(Physician)
‘What works really well is the really good communication
between the physicians and the nurse and the GP. So
we’re really quite proactive about chasing people and
communicating with each other exactly what we’re doing
and what needs to be done’. (GP)
Telehealth (videoconferencing) was used extensively.
The majority of key informants who had used telehealth
spoke positively about telehealth as an enabler to providing patient care and treatment.
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‘I think telehealth has got a role and I think it would
be good to expand’. (Physician)
Table 1 summarises the features identified by key informants as critical to the success of the WA regional nursesupported hepatitis C shared care model.
Model of care in regions without a nurse-supported hepatitis C shared care service

In regions without a nurse-supported hepatitis C shared
care program, both GP-driven and specialist-driven care
pathways for patients were evident and telehealth was used.
‘The liver clinic offers regions without a hepatitis C
nurse surrogate nurse support by telehealth. We did a
survey on telehealth and the patients were happy,
although they worry about confidentiality’. (Physician)
Patients were referred by GPs to a physician, if available,
or to tertiary centres.
‘The proportion of people that travel out of the region
for treatment is zero. People are either treated within
the region or they’re not treated because there’s no
capacity’. (Physician)
However, there appeared to be little awareness of what
happened to patients once they were referred. The lack of
local treatment follow-up for patients had implications for
local emergency departments since patients with side effects from treatment may present to local emergency
departments. A lack of GP involvement was also noted.
Table 1 Critical features of the WA regional nurse-supported
hepatitis C shared care model
Critical features of the WA regional nurse-supported hepatitis C shared
care model
Patient-centred care enabling patients to choose when to start treatment
depending on health status and personal or work commitments
Dedicated hepatitis nurse located regionally who is responsible for patient
education and coordinating all patient treatment and care including
follow up and monitoring of patients and patient referrals to allied
health services
Patient-centred care enabling patients to choose when to start treatment
depending on health status and personal or work commitments
Specialist physicians responsible for assessing patient’s health status,
initiating treatment, and refining treatment schedule as required
Collaboration with GPs where possible to help patients manage side
effects of treatment once initiated
Telehealth links between regional areas and tertiary liver clinics in Perth
for ongoing support and for referral of complex cases according to
agreed protocols
Excellent communications between nurse, GP, physician, and tertiary
centres
Continuity of care through stability of key roles
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‘Some GPs would like to get involved [in shared care]
and some don’t. I think you’ve got to nurture those
that do’. (Nurse)
Patient survey

Of the 47 patients invited to complete a survey, 22 (47 %)
returned a completed survey. Two (2) surveys did not meet
the requirements for the study and were excluded from
analysis. Very few comments were received. Respondents
ranged from 40 to 65 years of age. Table 2 shows the hepatitis C notification data (2010–2012) for the three regions
currently implementing regional nurse-supported hepatitis
C shared care services in Western Australia and outlines
the basic demographic characteristics of patients who
returned a survey.
Patient experiences of referral and treatment

The interval between referral and starting treatment
ranged from less than one month to over two years, with
a quarter of patients (25 %) reporting that they started
treatment three to six months between referral and
treatment.
Most patients identified the local ‘hepatitis C nurse’ or
the ‘hepatitis C nurse and other’ as the main person involved in explaining their treatment (80 %), scheduling their
appointments (60 %) and communicating their blood test
results (90 %). The majority of patients (90 %) also reported
it being ‘very easy’ or ‘easy’ to contact the hepatitis C nurse
(Table 3).
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Patient satisfaction

Patients reported high levels of satisfaction across the following three aspects of care: ‘Information received about
the side-effects of treatment’, ‘Level of support received
while on treatment’, ‘Overall experience of the hepatitis C
treatment program’ (Table 4).
Eighty-five per cent of respondents were either very satisfied (65 %) or slightly satisfied (20 %) with the way the
shared care program functioned in their area. Similarly, the
majority of patients (90 %) were very satisfied (65 %) or
slightly satisfied (25 %) with the level of support received
while on treatment. Patients who reported lower levels of
satisfaction requested more information on treatment side
effects and the process from referral to treatment.
Having a dedicated hepatitis nurse who was able to facilitate access to local treatment was identified as a critical
feature of the program. When asked what the favoured
option would be if hepatitis C treatment was not available
in their region, 12 (60 %) patients reported that they would
wait longer until treatment became available in the region,
three (15 %) patients reported that they would choose to
see a private specialist in their region and a further three
(15 %) patients indicated that they would travel to Perth for
treatment. Data were missing for one patient and one
patient was unsure.
Patient recommendations

Patients recommended that appointments with the regional
hepatitis nurse and liver specialist should be maintained

Table 2 Demographic characteristics of hepatitis C notifications (2010–2012) [2], patients engaged in regional nurse supported
shared care and survey respondents (June 2013) in the Kimberley, Great Southern and South West regions of Western Australiaa
Notifications (Newly acquired
and unspecified 2010 – 2012)
N (%)

Patients engaged in regional
nurse-supported shared care
program N (%)

Survey Respondents
N (%)

Kimberley

72 (16.9 %)

13 (25 %)

2 (10 %)

Great Southern

109 (25.6 %)

16 (31 %)

4 (20 %)

South West

244 (57.4 %)

22 (44 %)

14 (70 %)

Male

302 (71 %)

38 (74 %)

13 (65 %)

Female

123 (28.9 %)

13 (25 %)

7 (35 %)

≤49 years

328 (77 %)

23 (45 %)

5 (25 %)

≥50

97 (22.9 %)

28 (55 %)

15 (75 %)

Yes

74 (17.5 %)

2b (4 %)

0 (0 %)

No

338 (79.5 %)

49 (96 %)

20 (100 %)

Unknown

13 (3.0 %)

0

0

Total

425

51

20 (100 %)

Region

Gender

Age group (yrs)

Aboriginal

a

Column totals may not summate to the total due to missing data
b
No Aboriginal patients were receiving treatment at the time of the study, although two Aboriginal patients were still engaged in the shared-care
program post-treatment
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Table 3 The main person identified by patients as being involved in explaining treatment, scheduling appointments and
communicating blood test resultsa
Hepatitis C nurse

Local specialist

Hepatitis C nurse and other

General Practitioners

Explaining treatment

12 (60 %)

3 (15 %)

4 (20 %)b

1 (5 %)

Scheduling appointments

10 (50 %)

7 (35 %)

2 (10 %)b

0

2 (10 %)

c

0

Communicating blood test results

14 (75 %)

3 (15 %)

a

Row totals may not summate to the total due to missing data
b
‘Other’ included GP and specialist in local area
c
‘Other’ included specialist in local area and PathWest pathology services

regularly throughout treatment, as they were not only considered to be important but were also reassuring for
patients. One patient recommended that there should be
staff members available to temporarily fill the positions of
hepatitis nurse/specialists when they are on leave, which
was identified as a limitation of nurse supported shared
care in WA. The patient commented:
‘The only problem I had during treatment was when
my hepatitis nurse and my specialist went on holidays
at the same time. They need someone to fill in for
them’.
Communication between patients, nurses and specialists
was paramount to the overall satisfaction with the program
and patients recommended nurses and specialists to maintain regular contact with patients, especially regarding treatment progression and side effects throughout treatment.
Travel/distance was mentioned by many patients, with
one patient commenting on the length of time it took for
a travel claim to be accepted.2 Another patient indicated
that travelling a shorter distance to access medication
would better suit their needs. There were no further
patient comments about accessing medication although it
is understood that medication is usually dispensed from
the regional hospital pharmacy.
Two patients mentioned the blood test result process in
their responses. One respondent would rather blood test
results were sent directly to them and the other respondent
would like to receive blood test results more regularly. The
same respondent reported that they would have benefited
from being linked to a support group during treatment.

Discussion
This study evaluated the regional nurse-supported model
of hepatitis C shared care in Western Australia. The
findings indicated benefits for patients and health professionals including improved patient compliance and completion of treatment and reduced patient transport costs
to tertiary centres. The study findings were consistent
with those of other studies which identify a role for nurseled models of care in regional areas to improve service accessibility [14–16] and for hepatitis C shared care models
in the assessment and treatment of patients with HCV
infection, particularly marginalised populations such as
PWID and people in custodial settings [13, 21].
The waiting time to start treatment and the support
services available to patients undergoing hepatitis C
treatment in regions with a nurse-supported shared care
hepatitis C program, seemed to be comparable, if not
better, than in tertiary centres.
However, there was a limit to the number of patients
that a hepatitis nurse and physician could support (about
five to six patients per day that the nurse is employed).
Nurse resource allocations should therefore be considered
based on patient caseload in regional areas. This includes
patients currently on treatment and those patients who
require support post-treatment.
Participation of GPs in shared care services was considered to improve regional capacity to offer treatment to patients. However, there were very few incentives for GPs to
be involved and GPs in regional areas were in short supply
[17]. Other studies have suggested a minimum HCV patient caseload for GPs given the sometimes lengthy hiatus
between diagnosis and commencing treatment for some

Table 4 Patient satisfaction levels with differing aspects of care
Number of respondents
n = 20
Satisfaction level

Aspect of care
Information received about
the side-effects of treatment

Level of support received
while on treatment

Overall experience of the
hepatitis C treatment program

Very satisfied

12 (60 %)

13 (65 %)

13 (65 %)

Slightly satisfied

5 (25 %)

5 (25 %)

4 (20 %)

Slightly unsatisfied

2 (10 %)

2 (10 %)

1 (5 %)

Very unsatisfied

1 (5 %)

0

2 (10 %)

Total

20 (100 %)

20 (100 %)

20 (100 %)
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HCV patients which can result in a lack of GP confidence
and expertise if these skills are not required often [7]. In
our study, a scarcity of GPs in regional areas, the perceived characteristics of hepatitis C patients as being noncompliant with medication or inconsistent in attending
appointments, and the complexity of psychosocial issues
often experienced by hepatitis C patients presented challenges to starting treatment.
The majority of patients expressed high levels of satisfaction with the services available and patients preferred to
access treatment locally. However, since there is currently a
much wider cohort of people who are not accessing treatment, it is not possible to generalise based on the patient
data collected. For example, the results suggested that there
may be barriers to treatment uptake and engagement of
Aboriginal patients and younger patients in the shared care
program. Aboriginal people comprised approximately 21 %
of hepatitis C notifications in 2012 in the WA regions operating a shared care program. However, at the time of this
study no Aboriginal patients were receiving treatment
through the shared care program (although two Aboriginal
patients were later identified as receiving post-treatment
follow-up) [2]. Similarly, in 2012, notifications for newly
acquired and unspecified hepatitis C were highest in both
the 20 to 29 years and 50 years and over age groups
respectively [2] while most patients engaged in the shared
care programs were aged 50 years or older. The reasons for
these discrepancies are unclear and further investigation of
contributing factors is required. This may include understanding where Aboriginal people and younger people
access testing and receive their diagnosis, how long patients
wait before starting treatment, the reasons for delaying
treatment, assessment of culturally safe health services, and
the availability of allied health services.
In our study, health professionals perceived that the support of dedicated hepatitis C nurses helped to speed up
access to treatment and enabled high levels of treatment
compliance (>98 %). Telehealth was considered highly effective and a viable option when supported by appropriately
trained health professionals and clear treatment protocols.
This finding was consistent with another WA study [22]
and the findings of Project ECHO (Extension for Community Healthcare Outcomes) which found treatment of HCV
patients at 21 rural ECHO sites and prisons in New Mexico
using telehealth to be comparable to treatment of patients
at an HCV clinic in reaching a sustained virological
response [21].
For regions that did not have a hepatitis nurse, the barriers to a patient starting treatment were significant and
the likelihood was that patients would be unable to start
treatment unless they had a long-term GP and/or were
able to travel back and forth to tertiary liver services in
Perth (over 1500 km from some regional areas). Not having nurse-led programs was perceived to be detrimental to
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people living with hepatitis C in regional areas. The limited GP and physician capacity in these areas meant that
effective treatment could not be provided without nurse
support.
The decision to implement regional shared care services
needs to be considered carefully. For example, feasibility of
regional hepatitis C shared care models requires the availability of allied health services such as mental health and
drug and alcohol services in regional areas. In addition,
people living with hepatitis C can experience stigma and
discrimination and some patients in regional communities
may prefer to travel to tertiary centres for reasons of anonymity. Treatment and care options to suit individual preferences, including for those in hard to service geographical
areas, are therefore needed.
Methodological considerations

The purpose of this study was to evaluate the nursesupported hepatitis C shared care services in regional
WA. Three limitations of the study should be noted. First,
we were unable to follow up those patients who did not
return a survey following a reminder from their nurse.
The majority of surveys were completed in the South
West region of WA and therefore the results of the
patient survey were most representative of this region.
Second, data were collected from patients who were
currently engaged in the shared care program. The experiences of patients who were considering (or had declined)
engaging in shared care services were not possible to
collect. Finally, the participation of GPs in shared care
services was considered important by all key informants.
However, and perhaps related to GP capacity or motivation for participation in shared care, we were only able to
recruit one GP for this study. The reasons for limited GP
participation and strategies for increasing GP participation
in regional shared care services should be explored further. GP involvement in hepatitis C shared care services
may become more relevant when oral-only hepatitis C
treatments become available, and if these are able to be
prescribed by GPs.

Conclusions
Hepatitis nurses in regional areas can coordinate effective
patient treatment and care when supported by treatment
protocols and access to physicians and liver specialists as
needed. Telehealth was highly effective in regional areas
and a viable option when supported by appropriately
trained health professionals in the region. Our findings
indicated that the nurse-supported model reduced patient
transport costs to tertiary centres, accelerated access to
treatment and delivered high levels of treatment compliance (>98 %). Furthermore, the patients consulted in our
study preferred to access treatment locally and indicated
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that they would delay treatment if it was not available
locally.
The case for implementing shared care services should
be considered on a region by region basis taking into consideration factors such as patient caseload and regional
demographic profile, including the requirements of culturally and linguistically diverse populations, Aboriginal
people and an ageing population with hepatitis C, the capacity of GPs and physicians, and the availability of allied
health services. In some regions, dedicated hepatitis C
shared care services may inadvertently exacerbate the
experiences of already stigmatised populations and a range
of options should be made available.
Finally, GPs may have an increasing role to play in the
future treatment landscape of hepatitis C if new oral-only
treatments can be prescribed by GPs. It is timely to scrutinise and remove barriers to GP involvement in hepatitis C
shared care and further explore the role of primary care in
improving hepatitis C treatment uptake.

Endnotes
1
The term ‘Aboriginal’ is used in preference to ‘Aboriginal
and Torres Strait Islander’, in recognition that Aboriginal
people are the original inhabitants of WA. No disrespect is
intended to our Torres Strait Islander colleagues and
community.
2
All states and territories in Australia offer a Patient
Assisted Travel Scheme (PATS) which provides financial
support for travel and accommodation costs to assist patients in rural and remote areas to access specialised health
services if they are not available in their area. More information about the PATS in Western Australia is available at
http://healthywa.wa.gov.au/Healthy-WA/Articles/N_R/Patient-Assisted-Travel-Scheme-PATS.
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